Free tool
FAERS Monitor: Valchlor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202317 or its brand name (Valchlor, Mechlorethamine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,247
Serious
714
32% of reports
Hospitalization
248
Death reported
155
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus322
- application site pruritus224
- application site erythema220
- application site pain218
- erythema213
- condition aggravated194
- off label use179
- skin discolouration147
- rash132
- skin irritation112
- blister107
- death104
- application site discolouration102
- application site irritation101
- disease progression99
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 2 |
| 2014 | 30 |
| 2015 | 256 |
| 2016 | 441 |
| 2017 | 389 |
| 2018 | 253 |
| 2019 | 276 |
| 2020 | 311 |
| 2021 | 71 |
| 2022 | 65 |
| 2023 | 50 |
| 2024 | 51 |
| 2025 | 33 |
| 2026 | 19 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,912 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site discolourationSignal | 102 | 241.0 | 198.9 | 23,540 |
| application site painSignal | 218 | 93.6 | 82.4 | 19,692 |
| application site pruritusSignal | 224 | 93.3 | 82.4 | 20,188 |
| application site erythemaSignal | 220 | 79.2 | 69.8 | 16,794 |
| application site irritationSignal | 101 | 76.6 | 63.3 | 7,404 |
| skin discolourationSignal | 147 | 30.0 | 25.7 | 4,093 |
| skin irritationSignal | 112 | 22.9 | 19.1 | 2,328 |
| blisterSignal | 107 | 17.9 | 14.8 | 1,688 |
| erythemaSignal | 213 | 9.7 | 8.5 | 1,670 |
| pruritusSignal | 322 | 7.8 | 7.1 | 1,951 |
| disease progressionSignal | 99 | 7.8 | 6.5 | 587 |
| condition aggravatedSignal | 194 | 6.0 | 5.2 | 810 |
| rashSignal | 132 | 2.8 | 2.4 | 158 |
| off label use | 179 | 1.9 | 1.7 | 81 |
| death | 104 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.